Article Type
Changed
Mon, 12/17/2018 - 08:45
Display Headline
Risedronate prevents hip fractures, but who should get therapy?
The HIP trial
Article PDF
Author and Disclosure Information

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Issue
Cleveland Clinic Journal of Medicine - 69(12)
Publications
Topics
Page Number
964, 968-970, 973-976
Sections
Author and Disclosure Information

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Author and Disclosure Information

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Article PDF
Article PDF
The HIP trial
The HIP trial
Issue
Cleveland Clinic Journal of Medicine - 69(12)
Issue
Cleveland Clinic Journal of Medicine - 69(12)
Page Number
964, 968-970, 973-976
Page Number
964, 968-970, 973-976
Publications
Publications
Topics
Article Type
Display Headline
Risedronate prevents hip fractures, but who should get therapy?
Display Headline
Risedronate prevents hip fractures, but who should get therapy?
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media